
|Videos|April 19, 2022
Safety Data on Ruxolitinib in Primary MF
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, comments on safety data from the ruxolitinib clinical trials in patients with MF.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
The Targeted Pulse: Blood and Breast Cancer News
5







































